e-learning
resources
Munich 2014
Monday, 08.09.2014
Therapy of thoracic tumours: clinical trials and case series
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Safety and efficacy of erlotinib in patients with squamous cell lung cancer
M. Jakopovic, B. Cucevic, S. Plestina, S. Smojver-Jezek, S. Kukulj, N. Chalfe, M. Korsic, Z. Vrbica, G. Redzepi, M. Samarzija (Zagreb, Dubrovnik, Croatia)
Source:
International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Session:
Therapy of thoracic tumours: clinical trials and case series
Session type:
Thematic Poster Session
Number:
2722
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Jakopovic, B. Cucevic, S. Plestina, S. Smojver-Jezek, S. Kukulj, N. Chalfe, M. Korsic, Z. Vrbica, G. Redzepi, M. Samarzija (Zagreb, Dubrovnik, Croatia). Safety and efficacy of erlotinib in patients with squamous cell lung cancer. Eur Respir J 2014; 44: Suppl. 58, 2722
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
ALK/EML4 translocation in non-squamous NSCLC and their predictors
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Progression vs. pseudo progression in the treatment of squamous NSCLC with nivolumab
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
Treatment of advanced non-small cell lung cancer with trofosfamide
Source: Annual Congress 2013 –Advances in the therapy of lung cancer
Year: 2013
Surgical treatment outcomes on early-stages of non-small-cell lung cancer
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015
Improving survival for NSCLC patients in the national lung cancer audit
Source: International Congress 2015 – Quality management in lung cancer
Year: 2015
Algorithm of preoperative N-staging of non-small cell lung cancer
Source: Annual Congress 2013 –Oncological thoracic surgery
Year: 2013
Symptom-to-treatment intervals in lung cancer
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Methilation status in EBUS-NA samples of lung cancer
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014
Prognostic factors for survival in lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Second primary lung cancer in squamous NSCLC patients: The Nancy Biobank's database
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Electrospray-mediated local chemotherapy of lung carcinoma in mice
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016
Brain metastatic recurrence following radically treated lung cancer; a retrospective analysis
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
EBUS-TBNA for nodal restaging and relapse in lung cancer
Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours
Year: 2014
Comorbitities, responses and survival in pts with NSCLC
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
Functional impairment of NK cells in non-small-cell lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
The prognostic value of the tumor shrinkage rate for progression-free survival in patients with non-small cell lung cancer receiving gefitinib
Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours
Year: 2014
Chemotherapy beyond 3rd line in NSCLC – A retrospective analysis
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015
Predictors of lung cancer patients delay time in Serbia - a cross-sectional study
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept